Kilitch Drugs (India) Limited (KILITCH.NS) Valuation

Valuation

Model-based estimates, not advice. The DCF is the discounted-cash-flow value per share; compare it with the price, not as a target.

DCF fair value

-261.5%

-₹333.50

vs ₹206.49 price

Levered DCF

-₹750.38

After debt service

Piotroski score

2 / 9

Weak

Altman Z-score

—

Rating

C+

Overall 2 / 5

Ratios by fiscal year

Margins and yields are shares of revenue, equity or price; multiples are ×.

Metric	FY2026	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019
P/E	13.97×	21.7×	41.63×	20.73×	35.37×	33.14×	145.64×	72.4×
P/B	1.51×	2.8×	3.37×	1.4×	1.83×	0.96×	1.04×	2.29×
P/S	1.79×	2.86×	3.87×	1.52×	2.23×	1.78×	2.32×	3.36×
EV / EBITDA	10.31×	14.23×	21.13×	10.39×	19.78×	15.52×	30.86×	25.39×
Gross margin	38.8%	47.3%	47.6%	44.7%	29.5%	44.0%	21.0%	27.3%
Operating margin	14.0%	14.3%	13.7%	10.6%	7.9%	5.3%	-2.8%	8.3%
Net margin	12.8%	13.5%	9.5%	7.5%	6.4%	5.4%	1.6%	4.6%
Current ratio	1.83×	2.06×	2.27×	1.84×	1.65×	1.1×	2.54×	3.23×
Debt / equity	0.32×	0.24×	0.18×	0.15×	0.15×	0.12×	0.11×	0.08×
Interest coverage	5.93×	5.62×	3.5×	2.92×	6.75×	4.13×	-1.58×	10.6×
Dividend yield	0.0%	0.0%	0.0%	0.0%	0.5%	0.0%	1.4%	0.3%
Payout ratio	0.0%	0.0%	0.0%	0.0%	16.3%	0.0%	212.6%	24.8%

Key metrics by fiscal year

Metric	FY2026	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019
Return on equity	10.8%	13.2%	8.3%	6.9%	5.3%	2.9%	0.7%	3.2%
Return on invested capital	6.9%	8.2%	7.1%	5.9%	3.6%	1.8%	-0.6%	2.3%
Return on assets	6.6%	8.5%	6.1%	4.8%	3.5%	1.8%	0.6%	2.7%
Free cash flow yield	-19.1%	-5.2%	-1.1%	-0.6%	-0.9%	7.7%	-4.9%	-6.8%
Earnings yield	7.2%	4.7%	2.5%	4.9%	2.9%	3.0%	0.7%	1.4%
Enterprise value	₹4.9B	₹6.1B	₹6.1B	₹2.1B	₹2.7B	₹1.2B	₹1.3B	₹2.8B
Net debt / EBITDA	1.5×	0.93×	0.44×	0.11×	0.78×	0.3×	2.28×	0.22×
Cash conversion cycle (days)	14	20	76	-40	-38	-356	95	89